Association between histological features in temporal artery biopsies and clinical features of patients with giant cell arteritis

Israel Medical Association Journal

Volumn 15, Issue 6, 2013, Pages 271-274

  Breuer, Gabriel S ^a   Nesher, Ronit ^c   Reinus, Konstantin ^b   Nesher, Gideon ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HEBREW UNIVERSITY   (Israel)

^c MEIR MEDICAL CENTER   (Israel)

Author keywords

Acute phase reactants; Giant cell areritis (GCA); Intensity of the systemic inflammatory reaction (ISIR); Polymyalgia rheumatic; Temporal artery biopsy

Indexed keywords

PREDNISONE;

ANEMIA; ARTICLE; BLOOD VESSEL BIOPSY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DRUG DOSE INCREASE; ERYTHROCYTE SEDIMENTATION RATE; FEVER; FOLLOW UP; GIANT CELL; GIANT CELL ARTERITIS; HISTOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; ISCHEMIA; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; TEMPORAL ARTERY BIOPSY; THROMBOCYTOSIS; THROMBUS;

ADULT; BIOPSY; BLOOD SEDIMENTATION; FEMALE; GIANT CELL ARTERITIS; GIANT CELLS; HISTOLOGICAL TECHNIQUES; HUMANS; INFLAMMATION; MALE; PROGNOSIS; RANDOM ALLOCATION; REGRESSION ANALYSIS; STATISTICS AS TOPIC; SYMPTOM ASSESSMENT; TEMPORAL ARTERIES; TUNICA INTIMA;

EID: 84879538579     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Kaiser M, Weyand CM, Bjornsson J, Goronzy JJ. Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis. Arthritis Rheum 1998; 41: 623-33.
2. Makkuni D, Bharadwaj A, Wolfe K, Payne S, Hutchings A, Dasgupta B. Is intimal hyperplasia a marker of neuro-ophthalmic complications of giant cell arteritis? Rheumatology 2008; 47: 488-90.
3. Chatelain D, Duhaut P, Schmidt J, et al. Pathological features of temporal arteries in patients with giant cell arteritis presenting with permanent visual loss. Ann Rheum Dis 2009; 68: 84-8.
4. Armstrong AT, Tyler WB, Wood GC, Harrington TM. Clinical importance of the presence of giant cells in temporal arteritis. J Clin Pathol 2008; 61: 669-71.
5. Chatelain D, Duhaut P, Loire R, et al. Small-vessel vasculitis surrounding an uninflamed temporal artery: a new diagnostic criterion for polymyalgia rheumatica? Arthritis Rheum 2008; 58: 2565-73.
6. Breuer GS, Nesher R, Nesher G. Effect of biopsy length on the rate of positive temporal artery biopsies. Clin Exp Rheumatol 2009; 27 (Suppl 52): S10-13.
7. Breuer GS, Nesher G, Nesher R. Rate of discordant findings in bilateral temporal artery biopsy to diagnose giant cell arteritis. J Rheumatol 2009; 36: 794-6.
8. Nesher G, Nesher R, Mates M, Sonnenblick M, Breuer GS. Giant cell arteritis: intensity of the initial systemic inflammatory response and the course of the disease. Clin Exp Rheumatol 2008; 26 (Suppl 49): S30-4.
9. Cid MC, Font C, Oristrell J, et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 1998; 41: 26-32.
10. Gonzalez-Gay MA, Garcia-Porrua C, Amor-Dorado JC, Llorca J. Fever in biopsy-proven giant cell arteritis: clinical implications in a defined population. Arthritis Rheum 2004; 51: 652-5.
11. Nesher G, Berkun Y, Mates M, et al. Risk factors for cranial ischemic complications in giant cell arteritis. Medicine 2004; 83: 114-22.
12. Hayreh SS, Podhajsky PA, Zimmerman B. Ocular manifestations of giant cell arteritis. Am J Ophthalmol 1998; 125: 509-20.
13. Gonzalez-Gay MA, Lopez-Diaz MJ, Barros S, et al. Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients. Medicine 2005; 84: 277-90.
14. Hernandez-Rodriguez J, Garcia-Martinez A, Casademont J, et al. A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant cell arteritis. Arthritis Rheum 2002; 47: 29-35.
15. Hernandez-Rodriguez J, Segarra M, Vilardell C, et al. Tissue production of pro-inflammatory cytokines (IL-1 beta, TNF alpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant cell arteritis. Rheumatology 2004; 43: 294-301.
16. ter Borg EJ, Haanen HCM, Seldenrijk CA. Relationship between histological subtypes and clinical characteristics at presentation and outcome in biopsyproven temporal arteritis. Identification of a relatively benign subgroup. Clin Rheumatol 2007; 26: 529-32.
17. Stacy RC, Rizzo JF, Cestari DM. Subtleties in the histopathology of giant cell arteritis. Semin Ophthalmol 2011; 26: 342-8.